Author of

• 25535

  +

  Epidemiology and outcomes (ID 57)

  • Event: ELCC 2018
  • Type: Poster Discussion session
  • Track:
  • Presentations: 1
  • Moderators:A. Dingemans, D. Fennell
  • Coordinates: 4/13/2018, 14:45 - 15:45, Room W

  • 25543

    +

    215PD - Survival patterns in patients with malignant pleural mesothelioma using multimodality therapy (ID 525)

    10:59 - 10:59  |  Presenting Author(s): M. Hassan
    • Abstract

    Background:
    Malignant pleural mesothelioma (MPM) is no more considered a rare disease and its incidence is escalating. It became a must to develop innovative modalities for better survival rates. Up to date, there is no agreement on the effectiveness of multimodality in MPM patients. This study assesses the value of multimodality therapy and identify the demographic and pathological characteristics associated with better outcome.
    
    Methods:
    Using SEER database, we extracted the data of 681 patients with MPM from 2004 to 2013. We included all age groups and races, AJCC stages I-IV and all histopathological variants. Patients were divided into four groups according to the received intervention: surgery alone, surgery followed by radiotherapy, surgery and chemotherapy, and triple modality (combination of surgery, chemotherapy, and radiotherapy).
    
    Results:
    Out of 681 patients, 176 (25.8%) had surgery alone, 74 (10.9%) had surgery followed by radiotherapy, 307 (45.1%) had surgery and chemotherapy, and 124 (18.2%) had a combination of surgery, chemotherapy, and radiotherapy. Highest one-year survival rates were observed among patients had the triple modality (79.6%, p value 0.000) in comparison to surgery alone (37.9%), surgery followed by radiotherapy (70.3%) and combined surgery and chemotherapy (62.2%). There is a statistically significant relationship between receiving the triple modality and each of the race, age, histopathology and nodal involvement.Table:One year survival rates among patients received the triple modality

    Variables	Survival rates	N	P value
    Sex
    Male	76.8%	97	0.504
    Female	89.9%	27
    Age
    20–39	100%	1	0.000**
    40–59	94.1%	31
    60–79	76.5%	88
    >80	26.9%	4
    Race
    White	79.7%	115	0.017*
    Black	100%	3
    Other	67.5%	6
    Histopathology
    Sarcomatoid	15.0%	7	0.000**
    Epithelioid	81.9%	93
    Biphasic	89.1%	24
    N Stage
    N0	77.7%	63	0.02*
    N1	87.0%	35
    N2	73.7%	22
    N3	100%	3
    AJCC Stage
    II	82.4%	21	0.50
    III	85.5%	57
    IV	71.0%	46

    
    
    Conclusions:
    Survival rates of MPM patients are the highest when receiving combination of surgery, chemotherapy, and radiotherapy. Further investigations are needed to study the long-term outcomes.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    Mariam Hassan
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.